Summit Therapeutics (SMMT) return on equity (ROE)

Return on equity · fiscal 2025
-163.9%

Summit Therapeutics (SMMT) earned a return on equity of -163.9% in fiscal 2025 (the year ended December 31, 2025). That is 106.9 percentage points lower than the -56.9% of fiscal 2024. Figures as of 17 Nov 2026, 23:13 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
-163.9%
Change on fiscal 2024
−106.9 pts
Highest on record
18.9%fiscal 2019
Lowest on record
-791.5%fiscal 2023
Fiscal years on record
72019–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Summit Therapeutics return on equity (ROE), in more detail

Across the 7 fiscal years on record (2019–2025), the highest was 18.9% in fiscal 2019 and the lowest -791.5% in fiscal 2023. The fiscal 2025 figure is higher than in 17% of the 6 earlier fiscal years on record, whose median is -64.3%.

History · 7 fiscal years

Return on equity by fiscal year

Summit Therapeutics return on equity (ROE), year by year

Summit Therapeutics (SMMT) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
2025-163.9% 106.9 pts down
2024-56.9% 734.6 pts up
2023-791.5% 729.3 pts down
2022-62.2% 44.2 pts up
2021-106.4% 40.1 pts down
2020-66.3% 85.2 pts down
201918.9%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Summit Therapeutics and comparable companies
CompanyReturn on equityFiscal year
BridgeBio Pharma BBIO-872.9%2020
Summit Therapeutics SMMT-163.9%2025
Glaukos GKOS-28.6%2025
Encompass Health EHC23.2%2025
BrightSpring Health Services BTSG10.2%2025
Baxter International BAX-15.6%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on SMMT

Summit Therapeutics, figure by figure

Summit Therapeutics (SMMT) overview: price, valuation and scorecardAll health care companies by market value

Summit Therapeutics return on equity (ROE): questions and answers

What is Summit Therapeutics's return on equity?

Summit Therapeutics (SMMT) earned a return on equity of -163.9% in fiscal 2025 (the year ended December 31, 2025). That is 106.9 percentage points lower than the -56.9% of fiscal 2024.

Is Summit Therapeutics's return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 17% of the 6 earlier fiscal years on record, whose median is -64.3%.

What are the highest and lowest return on equity figures on record for Summit Therapeutics?

Across the 7 fiscal years on record (2019–2025), the highest was 18.9% in fiscal 2019 and the lowest -791.5% in fiscal 2023.

How is Summit Therapeutics's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Summit Therapeutics (SMMT) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/SMMT/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.